Can Entera Bio Ltd. (ENTX)’s Tomorrow be Different? The Stock Formed a Bearish Ascending Triangle Chart Pattern

November 10, 2018 - By whatsonthorold

The stock of Entera Bio Ltd. (ENTX) formed an ascending triangle with $4.87 target or 7.00 % below today’s $5.24 share price. The 8 months triangle pattern indicates high risk for the $59.88M company. If the $4.87 price target is reached, the company will be worth $4.19M less.
The ascending triangle is a questionable performer despite its reputation as a reliable chart pattern. The ascending triangle has break even failure rate for up and down breakouts of 13% and 11%, respectively. The average rise and decline is 35% and 19%. The throwback or so called pullback rates are: 57% and 49%. The stocks meeting their targets is high for this type of breakout: 75% and 68% percent.

The stock decreased 0.19% or $0.01 during the last trading session, reaching $5.24. About 1,500 shares traded. Entera Bio Ltd. (NASDAQ:ENTX) has 0.00% since November 10, 2017 and is . It has underperformed by 15.62% the S&P500.

More notable recent Entera Bio Ltd. (NASDAQ:ENTX) news were published by: which released: “Chesapeake Energy Corporation: Chesapeake Energy Corporation Reports 2018 Third Quarter Financial And …” on October 30, 2018, also with their article: “Sterling Bancorp: Sterling Bancorp announces results for the third quarter of 2018 with record earnings per share …” published on October 24, 2018, published: “Entera Bio Ltd. (ENTX) Highlights Positive Results from Part 1 of Phase 2 PK/PD Study of Oral PTH (1-34) in Patients …” on November 08, 2018. More interesting news about Entera Bio Ltd. (NASDAQ:ENTX) were released by: and their article: “Form 6-K Entera Bio Ltd. For: Nov 08” published on November 08, 2018 as well as‘s news article titled: “Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with …” with publication date: November 08, 2018.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company has market cap of $59.88 million. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It currently has negative earnings. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News